NASDAQ:NRXP
NRX Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc.'s revenue was $1.2M in fiscal 2025.Summary generated from NRX Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.2M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin58.8%
Operating margin−1324.4%
Net margin−2336.5%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 0 | 1 |
| Operating income | −116 | −44 | −28 | −19 | −16 |
| Net income | −93 | −40 | −30 | −25 | −29 |
| Free cash flow | −38 | −40 | −22 | −11 | n/a |
Recent filings
- 8-KEntry into a material agreement
Oct 5, 2026 - 8-KOther events
Sep 16, 2026 - 8-KRegulation FD disclosure
Sep 14, 2026 - 8-KResults of operations and financial condition
Aug 17, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KRegulation FD disclosure
Aug 7, 2026 - 8-KOther events
Jul 22, 2026 - 8-KEntry into a material agreement
Jun 4, 2026